Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?

作     者：Christoph G Dietrich Andreas Geier Uta Merle 

作者机构：Gastro-Praxis WiesbadenLeberzentrum WiesbadenWiesbaden 65189Germany Division of HepatologyDepartment of Medicine IIUniversity Hospital WuerzburgWuerzburg 97080Germany Department of Gastroenterology and HepatologyUniversity Hospital HeidelbergHeidelberg 69120Germany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2023年第29卷第2期

页      面：367-377页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：COVID-19 Postacute sequelae of COVID-19 Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Inflammation Fatty liver 

摘      要：The pandemics of coronavirus disease 2019(COVID-19)and non-alcoholic fatty liver disease(NAFLD)*** liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD,while preexisting liver damage from NAFLD may influence the course of ***,the prognostic relevance of this interaction,though,is *** is a risk factor for the presence of NAFLD as well as a severe course of *** studies reveal conflicting results regarding the influence of NAFLD presence on COVID-19 illness *** molecular similarities of cytokine pathways in both diseases,including postacute sequelae of COVID-19,suggest common pathways for chronic low-activity *** review will summarize existing data regarding the interaction of both diseases and discuss possible mechanisms of the influence of one disease on the other.